Compare · COR vs HKPD
COR vs HKPD
Side-by-side comparison of Cencora Inc. (COR) and Cellyan Biotechnology Co. Ltd (HKPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and HKPD operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $62.60B, about 3243.2x HKPD ($19.3M).
- COR has been more active in the news (10 items in the past 4 weeks vs 2 for HKPD).
- COR has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cencora Inc.
- Cellyan Biotechnology Co. Ltd
- Price
- -
- -
- Market cap
- $62.60B
- $19.3M
- 1M return
- +5.44%
- -
- 1Y return
- +13.22%
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 10
- 2
- Recent ratings
- 25
- 0
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Latest COR
- Executive Vice President Campbell Elizabeth S sold $3,662,663 worth of shares (11,300 units at $324.12), decreasing direct ownership by 37% to 19,455 units (SEC Form 4)
- RBC Capital Mkts initiated coverage on Cencora with a new price target
- Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form 10-Q filed by Cencora Inc.
- Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Reports Fiscal 2026 Third Quarter Results
- Director Nally Dennis M was granted 113 shares, increasing direct ownership by 0.86% to 13,188 units (SEC Form 4)
- Director Cooper Ellen was granted 97 shares, increasing direct ownership by 12% to 893 units (SEC Form 4)
- Director Tyler Lauren M was granted 97 shares, increasing direct ownership by 2% to 4,456 units (SEC Form 4)
Latest HKPD
- SEC Form S-8 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 20-F filed by Cellyan Biotechnology Co. Ltd
- SEC Form NT 20-F filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-3 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 3 filed by new insider Chan Kam Leung
- New insider Wong Lap Sun claimed ownership of 18,468 units of Class A Ordinary Shares (SEC Form 3)
- SEC Form 3 filed by new insider Wang Zifeng